glp 1 cgm GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome Intermittently Scanned CGM Reduced HbA1c

Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects

subcutaneous) and frequencies (daily vs

In clinical trials of Wegovy (FDA-approved semaglutide), participants achieved an average weight loss of approximately 15% over 68 weeks, with some participants achieving up to 20% with continued treatment and adherence, when combined with diet and exercise

Yerba mate intake led to reductions in blood pressure, inflammatory markers, LDL cholesterol (in healthy participants), and select metabolic and gastrointestinal hormones, alongside modest improvements in body composition among healthy individuals

Hypertension ISO